Privacy Statement

Adapt Pharma, Inc. respects the privacy of visitors to our websites, and as a result, we have developed this Online Privacy Statement. We may update this Statement from time to time.

SCOPE

This Privacy Statement applies only to the operation of websites that directly link to this Statement when you click on “Privacy Statement” in the website footer.

CONSENT TO PROCESSING IN THE UNITED STATES AND ELSEWHERE. This site is owned and operated by Adapt Pharma in the United States, but the information you provide may be accessible to our affiliates, vendors and suppliers in other countries. By using this site, you consent to the collection, storage and processing of your information in the United States and in any country to which we may transfer your information in the course of our business operations.

INFORMATION ROUTINELY COLLECTED BY OUR WEBSITE TECHNOLOGY

Web Log Data via Analytics Cookies. Our webservers will routinely gather web log data, sometimes from cookies on your computer, when you visit one of our websites. The webserver automatically recognizes non-personal information such as the date and time you visited our site, the pages you visited, the website you came from, the type of browser and operating system you are using, and the domain name and address of your Internet service provider. 

IP Address. We record the Internet Protocol, “IP,” address of your computer when you visit our site. Without more information, the IP address does not identify you personally, but it is what allows us to maintain communications with your computer as you move about our site and perform other site analytics. 

Cookies and Other Technologies. We also collect information about your use of our site through technology such as cookies and web beacons. A “web beacon” is a piece of code on our site that enables us to monitor things like user activity and site traffic. A “cookie” is a small file of letters and numbers that is stored on your browser or the hard drive of your computer if you agree.  Cookies contain information that is transferred to your computer's hard drive which allow us to keep track of your interests and preferences and recognize you as a return visitor to our site. We use cookies without directly identifiable personal information to bring you content and features likely to be of interest to you, based on your previous activities on our site. 

By continuing to browse the Website, you are agreeing to the use of cookies. If you do not agree to the use of cookies, please stop using the Website immediately. 

How We Use Your Information. Web log, IP address and other Information routinely collected by our webservers in connection with your visit to this website will be used to better understand your needs and general user traffic patterns, and to improve our websites and services. We may enhance or merge this information with other data we may have about you as well as with data obtained from third parties for the same purposes. We retain IP addresses and also may use your IP address to personalize content provided on the website. Information routinely collected may also be stored in databases owned and maintained by Adapt Pharma or its agents, contractors and business partners. Adapt Pharma retains all rights to these databases and the information contained in them.

Web Beacons. Our websites may use web beacons (sometimes called single-pixel GIFs) to generate web log information. 

Cookies. Our webservers can detect whether you have cookies on your computer. It is possible that a cookie may contain information that could be deemed identifiable. We may use the data we obtain through the use of cookies to customize your site experience by anticipating the information and services that may be of interest to you. We also analyze the information collected with cookie technology to help us improve the functioning of our site by monitoring traffic in popular areas and to modify the services and information we provide to meet customer demand. We use the information we collect through the use of cookies for our business purposes, including operation of our site, as well as research and product analyses to help us better market our products.

The cookies which are used

  • Strictly necessary cookies. These are cookies that are required for the operation of the Website.
  • Analytical/performance cookies. These allow Adapt Pharma to recognise and count the number of visitors and to see how visitors move around the Website when they are using it. This helps us to improve the way the Website works, for example, by ensuring that users are finding what they are looking for easily.
  • Functionality cookies. These are used to recognise you when you return to the Website.
  • Targeting cookies. These cookies record your visit to the Website, the pages you have visited and the links you have followed. Adapt Pharma will use this information to make the Website more relevant to your interests.

Third-Party Cookies and Advertising. Please note that third parties (including, for example, providers of external services such as web traffic analysis services, including Google Analytics) may also use cookies, over which Adapt Pharma has no control. These cookies are likely to be analytical/performance cookies or targeting cookies. We may partner with third-party ad networks to manage our advertising on other sites. Our ad network partners use cookies and web beacons to collect non-personally identifiable information about your activities on this and other websites to provide you targeted advertising based upon your interests.

If you would like to opt-out of or manage cookies used for targeted advertising, you may do so by following the options provided by the Network Advertising Initiative at: http://www.networkadvertising.org/choices/ and the Digital Advertising Alliance at: http://www.aboutads.info/choices/. Please note that opting out of receiving targeted ads will not prevent you from being served advertisements generally. 

Digital Analytics. Our webserver will install a cookie on your machine in order to aid the accuracy of our data analytics program. While a profile can be built from a user’s surfing habits through the use of this cookie, the cookie itself contains no personal information. We use these profiles to establish common web browsing of our users, such as links that have been clicked or documents accessed, which helps us to maintain and enhance the service we provide. This cookie will remain on your computer indefinitely, even after you leave our site. 

This Website uses Google Analytics, a web analytics service provided by Google, Inc. (“Google”). Google Analytics uses cookies (text files placed on your computer) to help website operators analyse how users use the site. The information gathered by Google Analytics does not identify any individual visitor. The information is aggregated and therefore anonymous.

Full details of the Google Analytics security and privacy principles can be found here.

The cookie-related information is not used to identify you personally, and these cookies are not used for any purpose other than those described above.

How to change your cookie settings
Most web browsers allow some control of most cookies through the browser settings. You can control and/or delete cookies as you wish. You can delete all cookies that are already on your computer and you can set most browsers to prevent them from being placed. However, if you do this, you may have to manually adjust some preferences every time you visit a site and some services and functionalities may not work. To find out more about cookies, including how to see what cookies have been set and how to manage and delete them, visit www.aboutcookies.org or www.allaboutcookies.org.

Sharing Your Information. We may share the information we collect through this website with our employees, agents, contractors or partners in connection with services that these individuals or entities perform for or with us. These agents, contractors or partners are restricted from using these data in any way other than to perform these services. Adapt Pharma expects our employees and partners to maintain the trust placed in us by those who provide us with information by using reasonable administrative, technical and physical safeguards. Adapt Pharma reserves the right to share information to respond to duly authorized information requests of governmental authorities or where required by law. In some circumstances, such as where national, state or company security is at issue, Adapt Pharma reserves the right to share our entire database with appropriate governmental authorities. We may also provide information to a third party in connection with the sale, assignment or other transfer of the business of this website to which the information relates. In which case, we will require any such buyer to agree to treat information in accordance with this Privacy Statement.

Social Media Plugins. Our websites may use social media plugins to enable you to easily share information with others. When you visit our websites, the operator of the social media plugin that is on our website can place a cookie on your computer, enabling that operator to recognize individuals on their website who have previously visited our sites. If you are logged into the social media website while browsing on our website, social media plugins may allow that social media website to receive directly identifiable information about you that shows you have visited our website. Social media plugins also allow the social media website to share information about your activities on our website with other users of their social media website. Adapt Pharma does not control any of the content from social media plugins. For more information about social media plugins from social media websites, you should refer to those sites' privacy and data sharing statements.

Do Not Track. Some web browsers may transmit “do-not-track” signals to websites with which the browser communicates. Adapt Pharma webservers do not currently respond to these signals.

Children. This site is not intended for or designed to attract individuals under the age of 18.

If you have any questions or comments about this Privacy Statement, please contact us by writing to:
Adapt Pharma, Inc.
100 Matsonford Road
Building 4, Suite 201
Radnor, PA 19087

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

Adverse Reactions: The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

To report SUSPECTED ADVERSE REACTIONS, contact ADAPT Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

References: 1. Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999–2016. NCHS Data Brief, no 294. Hyattsville, MD: National Center for Health Statistics. 2017/ CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA. 2. Surgeon General’s Advisory on Naloxone and Opioid Overdose. U.S. Department of Health and Human Services. Prevention. Guideline for prescribing opioids for chronic pain. Available at: www.cdc.gov/drugoverdose/prescribing/guideline.html. Accessed May 2018. 3. NARCAN® Nasal Spray. Prescribing Information. Adapt Pharma, Inc. Radnor, PA; 2017. 4. Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;165(4):245-52. 5. Centers for Disease Control and Prevention. Opioid Overdose. Available at: https://www.cdc.gov/drugoverdose/index.html. Accessed August 12, 2018. 6. World Health Organization. Information Sheet on Opioid Overdose. Available at: http://www.who.int/substance_abuse/information-sheet/en/. Accessed August 12, 2018. 7. Centers for Disease Control and Prevention. Guideline for prescribing opioids for chronic pain. Available at: www.cdc.gov/drugoverdose/prescribing/guideline.html. Accessed August 12, 2018. 8. CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics: 2015. 9. Krieter P, Chiang N, Gyaw S, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56(10):1243-53. 10. Mell HK et al. Emergency medical services response times in rural, suburban, and urban areas. JAMA Surg. 2017 Jul 19; [e-pub]. (http://dx.doi.org/10.1001/jamasurg.2017.2230). 11. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Chronic Pain – United States, 2016. Morb Mortal Wkly Rep. 2016;65(1):1-49. 12. National Safety Council. Prescription Opioid Painkiller Public Opinion Poll. October 2017. Available at: NSC.org. 13. CDC Wonder Database Multiple Cause of Death MCD - ICD-10 Codes: T40.1 (Heroin), T40.2 (Other Opioids), T40.3 (Methadone), T40.4 (Other synthetic narcotics) 2013.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

Adverse Reactions: The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

To report SUSPECTED ADVERSE REACTIONS, contact ADAPT Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

References: 1. Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999–2016. NCHS Data Brief, no 294. Hyattsville, MD: National Center for Health Statistics. 2017/ CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA. 2. Surgeon General’s Advisory on Naloxone and Opioid Overdose. U.S. Department of Health and Human Services. Prevention. Guideline for prescribing opioids for chronic pain. Available at: www.cdc.gov/drugoverdose/prescribing/guideline.html. Accessed May 2018. 3. NARCAN® Nasal Spray. Prescribing Information. Adapt Pharma, Inc. Radnor, PA; 2017. 4. Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;165(4):245-52. 5. Centers for Disease Control and Prevention. Opioid Overdose. Available at: https://www.cdc.gov/drugoverdose/index.html. Accessed August 12, 2018. 6. World Health Organization. Information Sheet on Opioid Overdose. Available at: http://www.who.int/substance_abuse/information-sheet/en/. Accessed August 12, 2018. 7. Centers for Disease Control and Prevention. Guideline for prescribing opioids for chronic pain. Available at: www.cdc.gov/drugoverdose/prescribing/guideline.html. Accessed August 12, 2018. 8. CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics: 2015. 9. Krieter P, Chiang N, Gyaw S, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56(10):1243-53. 10. Mell HK et al. Emergency medical services response times in rural, suburban, and urban areas. JAMA Surg. 2017 Jul 19; [e-pub]. (http://dx.doi.org/10.1001/jamasurg.2017.2230). 11. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Chronic Pain – United States, 2016. Morb Mortal Wkly Rep. 2016;65(1):1-49. 12. National Safety Council. Prescription Opioid Painkiller Public Opinion Poll. October 2017. Available at: NSC.org. 13. CDC Wonder Database Multiple Cause of Death MCD - ICD-10 Codes: T40.1 (Heroin), T40.2 (Other Opioids), T40.3 (Methadone), T40.4 (Other synthetic narcotics) 2013.